SCHEMBL4454711

SCHEMBL4454711

OCCOCCOCCOC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.55
DUT P33316 2/20 0.48
TK2 O00142 5/20 0.46
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 1/20 0.41
RECQL P46063 1/20 0.41
HRH4 Q9H3N8 1/20 0.40
TSHR P16473 2/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
ALOX15 P16050 1/20 0.38
SLC6A1 P30531 1/20 0.38
PPARG P37231 1/20 0.37
KCNH3 Q9ULD8 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
TK1 P04183 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26176904 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL26176883 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL26176911 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL26176881 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL24207815 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL3190599 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL24207971 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL2821674 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL3485522 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL26176900 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4649963-A2 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2025-11-19 EP disclosed
EP-3131588-B1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2025-11-05 EP disclosed
US-20240368179-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND METHODS OF USE UNIV YALE (US) 2024-11-07 US disclosed
US-20240299366-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2024-09-12 US disclosed
EP-3302572-B3 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2024-07-24 EP disclosed
US-11834460-B2 Imide-based modulators of proteolysis and associated methods of use YALE UNIVERSITY (US) 2023-12-05 US disclosed
US-20220112211-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE UNIV YALE (US) 2022-04-14 US disclosed
US-20220089570-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas, Inc. 2022-03-24 US disclosed
US-11220515-B2 Imide-based modulators of proteolysis and associated methods of use YALE UNIVERSITY (US) 2022-01-11 US disclosed
US-10947210-B2 Inhibitors of Hepatitis C virus polymerase COCRYSTAL PHARMA, INC. (US) 2021-03-16 US disclosed
US-8883764-B1 Formylpyrrole-based heterocycles for nucleic acid attachment to supports ILLUMINA, INC. (US) 2014-11-11 US disclosed
US-8883764-B1 Formylpyrrole-based heterocycles for nucleic acid attachment to supports ILLUMINA, INC. (US) 2014-11-11 US disclosed
US-20130197271-A1 DENDRIMERS AND METHODS OF PREPARING SAME THROUGH PROPORTIONATE BRANCHING UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2013-08-01 US disclosed
US-7598421-B2 Materials for the delivery of biologically-active material to cells UCL BIOMEDICA PLC (GB) 2009-10-06 US disclosed
US-7598421-B2 Materials for the delivery of biologically-active material to cells UCL BIOMEDICA PLC (GB) 2009-10-06 US disclosed
US-7598421-B2 Materials for the delivery of biologically-active material to cells UCL BIOMEDICA PLC (GB) 2009-10-06 US disclosed
WO-2005117985-A2 LIPOPOLYPLEX CONSTRUCT WITH AN INTEGRIN BINDING PEPTIDE FOR DELIVERY OF NUCLEIC ACIDS, PEPTIDES OR DRUGS UCL BIOMEDICA PLC (GB) 2005-12-15 WO disclosed
US-20050245446-A1 Materials for the delivery of biologically-active material to cells NANOGENICS LIMITED (GB) 2005-11-03 US disclosed
EP-0540612-A1 HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES Pharmacia AB (SE) 1993-05-12 EP disclosed
WO-1992001474-A1 HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES KABI PHARMACIA AB (SE) 1992-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245446-A1 Materials for the delivery of biologically-active material to cells ITGB1, ITGA2B, ITGB2 KIF11 2529/4885DUT 1642/4885TK2 1292/4885
US-11220515-B2 Imide-based modulators of proteolysis and associated methods of use CRBN, MDM2, UBE2N KIF11 3592/4885DUT 3191/4885TK2 3709/4885
US-20240299366-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE CRBN, MDM2, UBE2N KIF11 3592/4885DUT 3191/4885TK2 3709/4885
US-20220112211-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE CRBN, MDM2, UBE2N KIF11 3592/4885DUT 3191/4885TK2 3709/4885
US-20240368179-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND METHODS OF USE CRBN, MDM2, UBE2N KIF11 3462/4885DUT 3326/4885TK2 3776/4885
US-20220089570-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE CRBN, MDM2, UBE2N KIF11 3592/4885DUT 3191/4885TK2 3709/4885
US-10947210-B2 Inhibitors of Hepatitis C virus polymerase POLI, POLR2E, POLR2H KIF11 3908/4885DUT 183/4885TK2 1116/4885
US-11834460-B2 Imide-based modulators of proteolysis and associated methods of use CRBN, MDM2, UBE2N KIF11 3592/4885DUT 3191/4885TK2 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.